본문바로가기
About Us
SK bioscience
Company Overview
History
Vision
Contact Us
Leadership
Message from the CEO
Headquarters & Facilities
SK bioscience Headquarters
R&D Center
L HOUSE
Subsidiary
SK bioscience USA
IDT Biologika
Science & Technology
Pipeline
R&D
Production
Business
Business Overview
Domestic
Overseas Business
Vaccine Co-Development
and Technology Transfer
CDMO/CMO
Products
In-house Products
Outsourced Products
Global Partnerships
ESG
새창열기 아이콘
IR
Corporate Governance
Company Information
Financial Information
Financial Statements
Financial Credit
Audit Reports
Investment Information
Stock Prices
Shareholder Status
IR Documents
Disclosure
PR
Press Releases
Media Zoom
Brochure
CI Guideline
sitemap
About Us
SK bioscience
Company Overview
History
Vision
Contact Us
Leadership
Message from the CEO
Headquarters & Facilities
SK bioscience Headquarters
R&D Center
L HOUSE
Subsidiary
SK bioscience USA
IDT Biologika
Science & Technology
Pipeline
R&D
Production
Business
Business Overview
Domestic
Overseas Business
Vaccine Co-Development
and Technology Transfer
CDMO/CMO
Products
In-house Products
Outsourced Products
Global Partnerships
ESG
IR
Corporate Governance
Company Information
Financial Information
Financial Statements
Financial Credit
Audit Reports
Investment Information
Stock Prices
Shareholder Status
IR Documents
Disclosure
PR
Press Releases
Media Zoom
Brochure
CI Guideline
사이트맵 닫기
Language
KOR
ENG
LinkedIn
YouTube
ESG
SK careers
C/S
SK ethics
Q
U
I
C
K
PR
SK bioscience company news updates
PR
About Us
Science & Technology
Business
ESG
IR
PR
Press Releases
Press Releases
Media Zoom
Brochure
CI Guideline
Press releases
SK bioscience and IVI Announce 2024 Park MahnHoon Award Winners
2024.03.14
SK bioscience Appoints New Leaders in Quality Department to Strengthen Global Competitiveness
2024.03.11
SK bioscience Breaks Ground on Manufacturing Facility Expansion for Extending Product Pipeline
2024.03.07
SK bioscience Receives WHO Prequalification for Typhoid Conjugate Vaccine
2024.02.23
SK bioscience Receives A Grade in MSCI ESG Rating 2023
2024.01.05
SK bioscience CEO Joins Zero Disposable Challenge
2024.01.04
Administration of Novavax’s Updated COVID-19 Vaccine Will Begin in Korea on December 18
2023.12.12
SK bioscience and Sanofi Initiate Submission of Phase III Study Investigational New Drug Amendment to the U.S. FDA of 21-Valent Pneumococcal Conjugate Vaccine Candidate
2023.12.11
Novavax’s Updated COVID-19 Vaccine Receives Emergency Use Authorization in the Republic of Korea
2023.11.29
SK bioscience Expands L HOUSE for Preparing Commercialization of Next-Generation Pneumococcal Vaccine
2023.11.28
처음
이전
1
2
3
4
5
6
7
8
9
10
다음
끝
